Skip to content

Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01308983
Acronym
SAPHA
Enrollment
32
Registered
2011-03-04
Start date
2010-09-30
Completion date
Unknown
Last updated
2012-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prehypertension

Keywords

Prehypertension, Flow mediated dilation, Pulse wave velocity, carotid compliance, Prehypertension and amiloride

Brief summary

Primary Specific Aim: To test the hypothesis that amiloride will improve vascular health of young adults with prehypertension.

Interventions

DRUGAmiloride

Amiloride 10 mg orally once a day for 16 weeks

Sponsors

Augusta University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Prehypertensive: Having systolic BP between 120 to 139 mmHg and/or diastolic BP between 80 to 89 mmHg during screening visit. BP will be measured manually tree times at 10 minutes interval after subjects sit quietly for at least 5 minutes in a chair. The average of last two BP measurements will be taken into consideration. * Male or female of Caucasian or African-American origin. * No history of any major past and current medical illness (such as diabetes, renal disease, liver disease etc.) * Not taking any medication that affects blood pressure.

Exclusion criteria

* HbA1C \> 7.0 % during screening visit. * Serum potassium \> 5.5 mEq/L during screening and/or any testing visit due to risk of developing hyperkalemia. * Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 50 ml/min\* (Glomerular Filtration Rate Estimate by Abbreviated MDRD Study Equation)35 during screening and/or any testing visit due to risk of developing renal dysfunction. * Female having positive pregnancy test during screening and/or any testing visit.

Design outcomes

Primary

MeasureTime frameDescription
Vascular phenotypes16 weeks(Flow mediated dilation, Pulse wave velocity, and carotid artery compliance)

Countries

United States

Contacts

Primary ContactSamip J Parikh, MBBS, MPH
sparikh@georgiahealth.edu7067211764

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026